{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:09:53Z","timestamp":1782986993493,"version":"3.54.5"},"reference-count":26,"publisher":"Japanese Society of Veterinary Science","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Veterinary Medical Science","J. Vet. Med. Sci."],"published-print":{"date-parts":[[2016]]},"DOI":"10.1292\/jvms.15-0707","type":"journal-article","created":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T22:07:15Z","timestamp":1462399635000},"page":"1293-1298","source":"Crossref","is-referenced-by-count":10,"title":["Anti-tumor effects of perphenazine on canine lymphoma"],"prefix":"10.1292","volume":"78","author":[{"given":"Shunya","family":"TSUJI","sequence":"first","affiliation":[{"name":"Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677\u20131 Yoshida, Yamaguchi 753\u20138515, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"YABE","sequence":"additional","affiliation":[{"name":"Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677\u20131 Yoshida, Yamaguchi 753\u20138515, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"USUI","sequence":"additional","affiliation":[{"name":"Laboratory of Veterinary Toxicology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"MIZUNO","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"OHAMA","sequence":"additional","affiliation":[{"name":"Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677\u20131 Yoshida, Yamaguchi 753\u20138515, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"SATO","sequence":"additional","affiliation":[{"name":"Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677\u20131 Yoshida, Yamaguchi 753\u20138515, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"122","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bozulic, L. and Hemmings, B. A. 2009. PIKKing on PKB: regulation of PKB activity by phosphorylation. <i>Curr. Opin. Cell Biol.<\/i> 21: 256\u2013261.","DOI":"10.1016\/j.ceb.2009.02.002"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Brautigan, D. L. 2013. Protein Ser\/Thr phosphatases\u2014the ugly ducklings of cell signalling. <i>FEBS J.<\/i> 280: 324\u2013345.","DOI":"10.1111\/j.1742-4658.2012.08609.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Chen, J., Martin, B. L. and Brautigan, D. L. 1992. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. <i>Science<\/i> 257: 1261\u20131264.","DOI":"10.1126\/science.1325671"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Chen, J., Parsons, S. and Brautigan, D. L. 1994. Tyrosine phosphorylation of protein phosphatase 2A in response to growth stimulation and v-src transformation of fibroblasts. <i>J. Biol. Chem.<\/i> 269: 7957\u20137962.","DOI":"10.1016\/S0021-9258(17)37144-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Dhillon, A. S., Hagan, S., Rath, O. and Kolch, W. 2007. MAP kinase signalling pathways in cancer. <i>Oncogene<\/i> 26: 3279\u20133290.","DOI":"10.1038\/sj.onc.1210421"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Enjoji, S., Yabe, R., Fujiwara, N., Tsuji, S., Vitek, M. P., Mizuno, T., Nakagawa, T., Usui, T., Ohama, T. and Sato, K. 2015. The therapeutic effects of SET\/I2PP2A inhibitors on canine melanoma. <i>J. Vet. Med. Sci.<\/i> 77: 1451\u20131456.","DOI":"10.1292\/jvms.15-0193"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fujiwara, N., Kawasaki, H., Yabe, R., Christensen, D. J., Vitek, M. P., Mizuno, T., Sato, K. and Ohama, T. 2013. A potential therapeutic application of SET\/I2PP2A inhibitor OP449 for canine T-cell lymphoma. <i>J. Vet. Med. Sci.<\/i> 75: 349\u2013354.","DOI":"10.1292\/jvms.12-0366"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Garc\u00eda-Mart\u00ednez, J. M. and Alessi, D. R. 2008. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). <i>Biochem. J.<\/i> 416: 375\u2013385.","DOI":"10.1042\/BJ20081668"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Garrett, L. D., Thamm, D. H., Chun, R., Dudley, R. and Vail, D. M. 2002. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. <i>J. Vet. Intern. Med.<\/i> 16: 704\u2013709.","DOI":"10.1111\/j.1939-1676.2002.tb02411.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gutierrez, A., Pan, L., Groen, R. W., Baleydier, F., Kentsis, A., Marineau, J., Grebliunaite, R., Kozakewich, E., Reed, C., Pflumio, F., Poglio, S., Uzan, B., Clemons, P., VerPlank, L., An, F., Burbank, J., Norton, S., Tolliday, N., Steen, H., Weng, A. P., Yuan, H., Bradner, J. E., Mitsiades, C., Look, A. T. and Aster, J. C. 2014. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. <i>J. Clin. Invest.<\/i> 124: 644\u2013655.","DOI":"10.1172\/JCI65093"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Junttila, M. R., Puustinen, P., Niemel\u00e4, M., Ahola, R., Arnold, H., B\u00f6ttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., Lu, S. L., Lin, S., Chan, E. K., Wang, X. J., Gr\u00e8nman, R., Kast, J., Kallunki, T., Sears, R., K\u00e4h\u00e4ri, V. M. and Westermarck, J. 2007. CIP2A inhibits PP2A in human malignancies. <i>Cell<\/i> 130: 51\u201362.","DOI":"10.1016\/j.cell.2007.04.044"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kuo, Y. C., Huang, K. Y., Yang, C. H., Yang, Y. S., Lee, W. Y. and Chiang, C. W. 2008. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. <i>J. Biol. Chem.<\/i> 283: 1882\u20131892.","DOI":"10.1074\/jbc.M709585200"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Li, M., Makkinje, A. and Damuni, Z. 1996. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. <i>J. Biol. Chem.<\/i> 271: 11059\u201311062.","DOI":"10.1074\/jbc.271.19.11059"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Liu, Q. and Hofmann, P. A. 2004. Protein phosphatase 2A-mediated cross-talk between p38 MAPK and ERK in apoptosis of cardiac myocytes. <i>Am. J. Physiol. Heart Circ. Physiol.<\/i> 286: H2204\u2013H2212.","DOI":"10.1152\/ajpheart.01050.2003"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lu, J., Kovach, J. S., Johnson, F., Chiang, J., Hodes, R., Lonser, R. and Zhuang, Z. 2009. Inhibition of serine\/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i> 106: 11697\u201311702.","DOI":"10.1073\/pnas.0905930106"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Marconato, L. 2011. The staging and treatment of multicentric high-grade lymphoma in dogs: a review of recent developments and future prospects. <i>Vet. J.<\/i> 188: 34\u201338.","DOI":"10.1016\/j.tvjl.2010.04.027"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Millward, T. A., Zolnierowicz, S. and Hemmings, B. A. 1999. Regulation of protein kinase cascades by protein phosphatase 2A. <i>Trends Biochem. Sci.<\/i> 24: 186\u2013191.","DOI":"10.1016\/S0968-0004(99)01375-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. O\u2019Connor, C. M. and Wilson-Robles, H. 2014. Developing T cell cancer immunotherapy in the dog with lymphoma. <i>ILAR J.<\/i> 55: 169\u2013181.","DOI":"10.1093\/ilar\/ilu020"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Perrotti, D. and Neviani, P. 2013. Protein phosphatase 2A: a target for anticancer therapy. <i>Lancet Oncol.<\/i> 14: e229\u2013e238.","DOI":"10.1016\/S1470-2045(12)70558-2"},{"key":"20","unstructured":"20. Plumb, D. C. 2011. Plumb\u2019s veterinary drug handbook, 7th ed., Wiley-Blackwell, Oxford."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Saddoughi, S. A., Gencer, S., Peterson, Y. K., Ward, K. E., Mukhopadhyay, A., Oaks, J., Bielawski, J., Szulc, Z. M., Thomas, R. J., Selvam, S. P., Senkal, C. E., Garrett-Mayer, E., De Palma, R. M., Fedarovich, D., Liu, A., Habib, A. A., Stahelin, R. V., Perrotti, D. and Ogretmen, B. 2013. Sphingosine analogue drug FTY720 targets I2PP2A\/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. <i>EMBO Mol. Med.<\/i> 5: 105\u2013121.","DOI":"10.1002\/emmm.201201283"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Valli, V. E., Kass, P. H., San Myint, M. and Scott, F. 2013. Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival. <i>Vet. Pathol.<\/i> 50: 738\u2013748.","DOI":"10.1177\/0300985813478210"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Xing, Y., Li, Z., Chen, Y., Stock, J. B., Jeffrey, P. D. and Shi, Y. 2008. Structural mechanism of demethylation and inactivation of protein phosphatase 2A. <i>Cell<\/i> 133: 154\u2013163.","DOI":"10.1016\/j.cell.2008.02.041"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Yabe, R., Fujiwara, N., Mizuno, T., Usui, T., Ohama, T. and Sato, K. 2014. Characterization of SET\/I2PP2A isoforms in dogs. <i>J. Vet. Med. Sci.<\/i> 76: 1235\u20131240.","DOI":"10.1292\/jvms.14-0209"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Zhang, C., Cooper, D. E., Grevengoed, T. J., Li, L. O., Klett, E. L., Eaton, J. M., Harris, T. E. and Coleman, R. A. 2014. Glycerol-3-phosphate acyltransferase-4-deficient mice are protected from diet-induced insulin resistance by the enhanced association of mTOR and rictor. <i>Am. J. Physiol. Endocrinol. Metab.<\/i> 307: E305\u2013E315.","DOI":"10.1152\/ajpendo.00034.2014"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Zonta, F., Pagano, M. A., Trentin, L., Tibaldi, E., Frezzato, F., Trimarco, V., Facco, M., Zagotto, G., Pavan, V., Ribaudo, G., Bordin, L., Semenzato, G. and Brunati, A. M. 2015. Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. <i>Blood<\/i> 125: 3747\u20133755.","DOI":"10.1182\/blood-2014-12-619155"}],"container-title":["Journal of Veterinary Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/78\/8\/78_15-0707\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T22:13:55Z","timestamp":1655676835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/78\/8\/78_15-0707\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1292\/jvms.15-0707","relation":{},"ISSN":["0916-7250","1347-7439"],"issn-type":[{"value":"0916-7250","type":"print"},{"value":"1347-7439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}